ClinicalTrials.gg

Program

vamikibart

Also written as “Vamikibart”, “RO7200220” and “EBI-031”.

Its studies are mostly in Macular Edema, led by 2 companies.

Furthest: phase 3, since Dec 6, 20226 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche50 open or runningphase 3since Dec 6, 2022Dec 8, 2021none ahead
Eleven Biotherapeutics10 open or runningphase 1since Jul 19, 2016Jul 19, 2016none ahead
  • Named in Hoffmann-La Roche’s own pipeline as RG6179 vamikibart, phase 4, as of Oct 22, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 19, 2016First study: phase 1 study in Diabetic Macular EdemaNew to Eleven BiotherapeuticsEleven Biotherapeutics · NCT02842541
  2. Dec 8, 2021Hoffmann-La Roche's first studies: 2 phase 2 studies in Diabetic Macular EdemaNew to Hoffmann-La RocheHoffmann-La Roche · NCT05151744, NCT05151731
  3. Dec 6, 20222 phase 3 studies in Uveitic Macular EdemaHoffmann-La Roche · NCT05642325, NCT05642312
  4. Jan 8, 2025Phase 1 study in Diabetic Macular EdemaHoffmann-La Roche · NCT06771271 · 85 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06771271Diabetic Macular Edema · United States1CompletedHoffmann-La RocheNov 13, 202385
NCT05642325Uveitic Macular Edema · United States, Argentina, Australia and more3CompletedHoffmann-La RocheMay 7, 2025256
NCT05642312Uveitic Macular Edema · United States, Austria, Brazil and more3CompletedHoffmann-La RocheDec 9, 2024245
NCT05151744Diabetic Macular Edema · United States, Argentina, Canada and more2CompletedHoffmann-La RocheApr 17, 2024187
NCT05151731Diabetic Macular Edema · United States, Argentina, Canada and more2CompletedHoffmann-La RocheNov 6, 2024394
NCT02842541Diabetic Macular Edema1WithdrawnEleven BiotherapeuticsOct 20170

How it is read

Names in the registry

  • “Vamikibart”, 4 entries
  • “RO7200220”, 1 entry
  • “EBI-031”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.